Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Bhavesh Mohan Lal, Toshali Pandey, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy, Jr, Fenghuang Zhan, Eric Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2024-206497

Published: 2024

Journal Articles

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

Yihao Zhan, Hongling Peng, David E. Mery, Eric Siegel, Clyde Bailey, Catherine Ma, Hongwei Xu, Daisy V. Alapat, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1904.

https://doi.org/10.1182/blood-2024-203848

Published: 2024

Journal Articles

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Alissa Visram, Rajshekhar Chakraborty, Gregory R Pond, Hsien Seow, Anastasia Gayowsky, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alejandro Garcia-Horton, Rafael Fonseca, Hira Mian

Blood (2024) 144 (Supplement 1): 5170.3.

https://doi.org/10.1182/blood-2024-200956

Published: 2024

Journal Articles

Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting

Abeer Yaseen, Mohammad Ma'koseh, Albatol Alamoush, Anas Zayed, Mona Ribie, Marah Alzubi, Jawad Alrawabdeh, Rozan Alfar, Waleed Kamel Da'Na, Salwa Shihadeh Saadeh, Yazan Talab, Husam Abu Jazar, Samer Al-Hadidi, Sameer Yaser, Zaid Abdel Rahman

Blood (2024) 144 (Supplement 1): 2277.

https://doi.org/10.1182/blood-2024-205094

Published: 2024

Journal Articles

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Blood (2024) 144 (Supplement 1): 4729.

https://doi.org/10.1182/blood-2024-193583

Published: 2024

Journal Articles

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2024-199278

Published: 2024

Journal Articles

Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy, Jr, Fenghuang Zhan, Eric Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 3789.

https://doi.org/10.1182/blood-2024-204228

Published: 2024

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Journal Articles

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Sharmilan Thanendrarajan, Phil Farmer, Clyde Bailey, Carolina Schinke, Samer Al Hadidi, Maurizio Zangari, Stephanie Rogers, Anne Williams, Fenghuang Zhan, John D Shaughnessy, Jr, Tanvi H. Patel, Anup Kumar Trikannad, Asis Shrestha, Syed Naqvi, Hira Imad Cheema, Trilok Shrivastava, Manozna Karri, Ramya Bachu, Frits van Rhee

Blood (2024) 144 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2024-206152

Published: 2024

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Journal Articles

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 254.

https://doi.org/10.1182/blood-2024-210725

Published: 2024

Journal Articles

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, Suzanne Lentzsch, Frits van Rhee, Anita D'Souza, Rajshekhar Chakraborty, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke

Blood (2024) 144 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2024-210478

Published: 2024

Journal Articles

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

Jehad Almasri, Bashar Hasan, Zin Tarakji, Faris W. Naffa', Lynn Warner, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 6986.

https://doi.org/10.1182/blood-2024-206645

Published: 2024

Journal Articles

Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Nishanth Thalambedu, Jeffery Sawyer, Janet L Lukacs, Phil Farmer, Samer Al-Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, Maurizio Zangari

Blood (2024) 144 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2024-211798

Published: 2024

Journal Articles

Identification of Risk Factors for Myeloma Progression in African American Patients

David E. Mery, Yihao Zhan, Hongling Peng, Eric Siegel, Cody Ashby, Clyde Bailey, Catherine Ma, Hongwei Xu, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, Guido Tricot, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 1937.

https://doi.org/10.1182/blood-2024-212173

Published: 2024

Journal Articles

Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression

Catherine Ma, Fumou Sun, Clyde Bailey, Hongwei Xu, Samer Al Hadidi, Carolina Schinke, Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, John D Shaughnessy, Jr, Fenghuang Zhan

Blood (2024) 144 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2024-204135

Published: 2024

Journal Articles

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

Samer Al Hadidi, Obada Ababneh, Carson W Ercanbrack, Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert Smith, Susan Panozzo, Guido Tricot, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Maurizio Zangari, Frits van Rhee

Blood (2023) 142 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2023-181034

Published: 2023

Journal Articles

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions

Fumou Sun, Yan Cheng, Jin-Ran Chen, Visanu Wanchai, David E. Mery, Hongwei Xu, Dongzheng Gai, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, John D Shaughnessy, Jr, Guido Tricot, Fenghuang Zhan

Blood (2023) 142 (Supplement 1): 452.

https://doi.org/10.1182/blood-2023-181853

Published: 2023

Journal Articles

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

Carolina Schinke, Leo Rasche, Cody Ashby, Rudy van Hemert, Sharmilan Thanendrarajan, Samer Al Hadidi, Maurizio Zangari, Clyde Bailey, Daisy V. Alapat, John D Shaughnessy, Jr, Fenghuang Zhan, Bart Barlogie, Frits van Rhee, Niels Weinhold

Blood (2023) 142 (Supplement 1): 882.

https://doi.org/10.1182/blood-2023-180896

Published: 2023

Journal Articles

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Blood (2023) 142 (Supplement 1): 545.

https://doi.org/10.1182/blood-2023-174875

Published: 2023

NARROW

Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience

The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting

Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Identification of Risk Factors for Myeloma Progression in African American Patients

Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression

Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions

Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only